Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
In 2019, the US FDA approved bremelanotide subcutaneous injection (Vyleesi, AMAG Pharmaceuticals) for the treatment of acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women making it only the second approved pharmacotherapy for female sexual dysfunction and the first melanocortin-based medicine to reach clinical approval
Note: We cannot give medical advice here
It predominantly localizes to the cellular membrane of diverse cell types throughout the human body
Controlled environments reduce this risk
US$ 25.72
US$ 21.21
US$ 27.31
US$ 21.95
US$ 20.80
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
